Herbert Newton is a Neurology physician affiliated with University Hospitals. OpenAlex indexes 231 publications with 5,323 citations (h-index 37); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
Sponsor: Ohio State University Comprehensive Cancer Center
- Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
Sponsor: Ohio State University Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- NovocureProgram year20251 paymentResearch$3,769
- SERVIER PHARMACEUTICALS LLCProgram year20251 payment$1,350
- Novocure Inc.Program year20253 payments$267
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
46%Other antiepileptics38.4%Levetiracetam77%Lacosamide23%Part D<11 patientsGabapentinoids3.8%Gabapentin100%Part D<11 patients+ 1 more class in this area
Sensory organs
23.5%Corticosteroid23.5%Dexamethasone100%Part D≥33 patientsMetabolism & gastrointestinal
17.3%Serotonin-3 Receptor Antagonist11.7%Ondansetron Hcl100%Part D≥23 patientsProton pump inhibitor5.6%Pantoprazole Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Amrou Sarraj, MD
University Hospitals
Leland Metheny, MD
University Hospitals
Sarah Mowry, MD
University Hospitals
Sepideh Amin-Hanjani, MD
University Hospitals
Bruce Miller, MD
University of California, San Francisco (UCSF)
David Knopman, MD
Mayo Clinic Rochester
Brett Kissela, MD
Medical College of Wisconsin
Richard Lipton, MD
Albert Einstein College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”